Asset Details
Do you wish to reserve the book?
Targeting inflammation in the treatment of type 2 diabetes: time to start
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
Targeting inflammation in the treatment of type 2 diabetes: time to start
Do you wish to request the book?
Targeting inflammation in the treatment of type 2 diabetes: time to start
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
Targeting inflammation in the treatment of type 2 diabetes: time to start
2014
Overview
Key Points
Inflammation has an important role in the pathogenesis of type 2 diabetes and associated complications.
Clinical studies have demonstrated that interleukin-1 (IL-1) antagonists, salsalate and tumour necrosis factor (TNF) antagonists improve glucose metabolism.
Anti-inflammatory drugs may have disease-modifying and long-lasting effects.
Future genetic and biomarker studies may profile responders to a specific anti-inflammatory treatment.
Combining or sequentially using multiple anti-inflammatory drugs may provide a tailored solution for treating patients with type 2 diabetes.
Inflammation is now appreciated to have an important role in the pathogenesis of type 2 diabetes and associated complications. Donath describes the underlying mechanisms and discusses the rationale for the use of anti-inflammatory agents — such as those that have been developed for rheumatoid arthritis and other diseases driven by inflammatory processes — in patients with diabetes.
The role of inflammation in the pathogenesis of type 2 diabetes and associated complications is now well established. Several conditions that are driven by inflammatory processes are also associated with diabetes, including rheumatoid arthritis, gout, psoriasis and Crohn's disease, and various anti-inflammatory drugs have been approved or are in late stages of development for the treatment of these conditions. This Review discusses the rationale for the use of some of these anti-inflammatory treatments in patients with diabetes and what we could expect from their use. Future immunomodulatory treatments may not target a specific disease, but could instead act on a dysfunctional pathway that causes several conditions associated with the metabolic syndrome.
Publisher
Nature Publishing Group UK,Nature Publishing Group
Subject
/ Animals
/ Anti-Inflammatory Agents - adverse effects
/ Anti-Inflammatory Agents - pharmacology
/ Anti-Inflammatory Agents - therapeutic use
/ Diabetes Complications - prevention & control
/ Diabetes Mellitus, Type 2 - complications
/ Diabetes Mellitus, Type 2 - drug therapy
/ Diabetes Mellitus, Type 2 - immunology
/ Diabetes Mellitus, Type 2 - metabolism
/ Drug Evaluation, Preclinical
/ Drugs, Investigational - adverse effects
/ Drugs, Investigational - pharmacology
/ Drugs, Investigational - therapeutic use
/ Humans
/ Metabolic Syndrome - complications
/ Metabolic Syndrome - prevention & control
